Phase II Trial of Sorafenib in Advanced Thyroid Cancer

PURPOSE: Given the molecular pathophysiology of thyroid cancer and the spectrum of kinases inhibited by sorafenib, including Raf kinase, vascular endothelial growth factor receptors, platelet-derived growth factor receptor, and RET tyrosine kinases, we conducted an open-label phase II trial to deter...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gupta-Abramson, Vandana, Troxel, Andrea B., Nellore, Anoma, Puttaswamy, Kanchan, Redlinger, Maryann, Ransone, Kathy, Mandel, Susan J., Flaherty, Keith T., Loevner, Laurie A., O'Dwyer, Peter J., Brose, Marcia S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2008
Assuntos:
Head and Neck Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2653134/
https://ncbi.nlm.nih.gov/pubmed/18541894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.3279
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados